Profile data is unavailable for this security.
About the company
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on four core programs: Large B-Cell Lymphoma (LBCL), Chronic Lymphocytic Leukemia (CLL), Autoimmune Disease and Renal Cell Carcinoma. It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL and CLL. Its pipeline also includes ALLO-316, ALLO-329 and ALLO-647.
- Revenue in USD (TTM)65.00k
- Net income in USD-279.42m
- Incorporated2017
- Employees232.00
- LocationAllogene Therapeutics Inc210 East Grand AvenueSOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (650) 457-2700
- Fax+1 (302) 636-5454
- Websitehttps://allogene.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Arcturus Therapeutics Holdings Inc | 163.87m | -71.96m | 568.43m | 180.00 | -- | 2.20 | -- | 3.47 | -2.68 | -2.68 | 6.11 | 9.56 | 0.40 | -- | 12.19 | 910,366.70 | -17.57 | -19.66 | -22.59 | -24.90 | -- | -- | -43.92 | -77.55 | -- | -- | 0.00 | -- | -19.03 | 60.31 | -417.95 | -- | 14.44 | -- |
Q32 Bio Inc | 0.00 | -65.02m | 568.86m | 41.00 | -- | 16.88 | -- | -- | -16.24 | -16.24 | 0.00 | 2.79 | 0.00 | -- | -- | 0.00 | -31.38 | -34.98 | -36.35 | -37.92 | -- | -- | -- | -971.76 | -- | -- | 0.2725 | -- | -63.97 | -26.32 | -2,156.96 | -- | -60.90 | -- |
Tourmaline Bio Inc | 0.00 | -35.69m | 579.49m | 44.00 | -- | 1.71 | -- | -- | -2.54 | -2.54 | 0.00 | 13.19 | 0.00 | -- | -- | 0.00 | -14.16 | -- | -14.64 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.99 | -- | -- | -- |
Alector Inc | 55.28m | -160.66m | 597.55m | 245.00 | -- | 3.97 | -- | 10.81 | -1.81 | -1.81 | 0.6162 | 1.55 | 0.0864 | -- | -- | 226,536.90 | -25.11 | -20.00 | -32.15 | -23.81 | -- | -- | -290.66 | -124.07 | -- | -- | 0.00 | -- | -27.36 | 28.52 | 2.19 | -- | 4.79 | -- |
Mineralys Therapeutics Inc | 0.00 | -119.67m | 601.69m | 28.00 | -- | 2.07 | -- | -- | -2.71 | -2.71 | 0.00 | 5.84 | 0.00 | -- | -- | 0.00 | -39.26 | -- | -41.62 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -141.28 | -- | -- | -- |
Third Harmonic Bio Inc | 0.00 | -32.74m | 605.37m | 42.00 | -- | 2.34 | -- | -- | -0.8204 | -0.8204 | 0.00 | 6.31 | 0.00 | -- | -- | 0.00 | -11.87 | -- | -12.10 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12.32 | -- | -- | -- |
Lenz Therapeutics Inc | 0.00 | -72.31m | 607.13m | 6.00 | -- | 2.96 | -- | -- | -9.45 | -9.45 | 0.00 | 7.46 | 0.00 | -- | -- | 0.00 | -29.53 | -- | -30.84 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.35 | -- | -- | -- |
Allogene Therapeutics Inc | 65.00k | -279.42m | 608.51m | 232.00 | -- | 1.18 | -- | 9,361.76 | -1.59 | -1.59 | 0.0004 | 2.46 | 0.00009 | -- | -- | 280.17 | -39.41 | -28.46 | -42.15 | -30.21 | -- | -- | -429,881.50 | -1,123.44 | -- | -- | 0.00 | -- | -39.10 | -- | 3.86 | -- | -14.06 | -- |
Lexicon Pharmaceuticals Inc | 3.64m | -202.11m | 610.92m | 285.00 | -- | 2.55 | -- | 167.79 | -0.7783 | -0.7783 | 0.0139 | 0.6639 | 0.0106 | 0.7239 | 2.20 | 12,775.44 | -58.57 | -24.41 | -63.55 | -29.01 | 92.47 | 98.49 | -5,550.87 | -84.92 | 11.49 | -11.96 | 0.2931 | -- | 766.19 | -54.71 | -73.74 | -- | 37.68 | -- |
Regenxbio Inc | 89.04m | -241.08m | 617.79m | 344.00 | -- | 1.77 | -- | 6.94 | -5.27 | -5.27 | 1.93 | 7.06 | 0.1423 | -- | 4.03 | 258,848.80 | -38.52 | -16.75 | -46.55 | -19.08 | 56.78 | 78.27 | -270.74 | -72.06 | -- | -- | 0.00 | -- | -19.94 | -16.21 | 6.00 | -- | -5.59 | -- |
Alumis Inc | -100.00bn | -100.00bn | 618.57m | 128.00 | -- | -- | -- | -- | -- | -- | -- | 3.87 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -38.47 | -- | -- | -- |
Corbus Pharmaceuticals Holdings Inc | 0.00 | -34.97m | 622.67m | 19.00 | -- | 4.74 | -- | -- | -5.82 | -5.82 | 0.00 | 10.92 | 0.00 | -- | -- | 0.00 | -35.74 | -86.84 | -45.03 | -130.46 | -- | -- | -- | -769.76 | -- | -29.78 | 0.0794 | -- | -- | -- | -5.33 | -- | -- | -- |
Y-mAbs Therapeutics Inc | 86.55m | -24.61m | 623.98m | 100.00 | -- | 6.54 | -- | 7.21 | -0.5618 | -0.5618 | 1.98 | 2.14 | 0.6262 | 1.42 | 4.19 | 865,460.00 | -17.81 | -44.23 | -23.58 | -50.45 | 88.74 | -- | -28.44 | -181.13 | 2.72 | -- | 0.00 | -- | 29.96 | -- | 77.58 | -- | -- | -- |
Humacyte Inc | 0.00 | -139.66m | 650.46m | 183.00 | -- | -- | -- | -- | -1.26 | -1.26 | 0.00 | -0.237 | 0.00 | -- | -- | 0.00 | -91.17 | -- | -100.75 | -- | -- | -- | -- | -- | -- | -40.08 | -- | -- | -100.00 | -- | -825.83 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 31.25m | 14.95% |
BlackRock Fund Advisorsas of 30 Jun 2024 | 9.43m | 4.51% |
The Vanguard Group, Inc.as of 30 Jun 2024 | 8.01m | 3.83% |
SSgA Funds Management, Inc.as of 30 Jun 2024 | 7.67m | 3.67% |
Capital Research & Management Co. (World Investors)as of 30 Jun 2024 | 6.90m | 3.30% |
T. Rowe Price Associates, Inc. (Investment Management)as of 30 Jun 2024 | 5.70m | 2.73% |
PRIMECAP Management Co.as of 30 Jun 2024 | 5.67m | 2.71% |
Woodline Partners LPas of 30 Jun 2024 | 4.36m | 2.09% |
Two Sigma Investments LPas of 30 Jun 2024 | 2.96m | 1.42% |
Wildcat Capital Management LLCas of 30 Jun 2024 | 2.92m | 1.40% |